This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least two infusions of rituximab, six months apart and are willing to be switched to ocrelizumab compared to a 100 patients who are continuing on rituximab as a comparison cohort from the clinic population treated as part of clinical care.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of Infusions With >= 1 IRR Between the Switching and Comparator Groups
Timeframe: Day 1, Day 15, Week 24
Difference in the Total Number of IRRs After Each Infusion of Ocrelizumab Compared to Rituximab Infusions in the Comparator Group.
Timeframe: Pre-study (Enrollment), Day 1, Day 15, Week 24
Severity of IRRs Following the Day 1 Infusion of Ocrelizumab in the Switching and the Comparator Groups Infusions
Timeframe: Day 1, pre-study infusions
Severity of IRRs Following the Day 15 Infusion of Ocrelizumab in the Switching and the Comparator Groups Infusions
Timeframe: Day 15, pre-study infusions
Severity of IRRs Following the Week 24 Infusion of Ocrelizumab in the Switching and the Comparator Groups Infusions
Timeframe: Week 24, pre-study infusions
Proportion of Patients With an IRR at Day 1 Versus Day 15 and Week 24 Infusions
Timeframe: Day 1, Day 15, Week 24